June 26 (Reuters) - Savara on Wednesday said its experimental drug, molgradex, met the main goal of a late-stage trial for treating a rare lung disease characterized by a feeling of breathlessness. (Reporting by Pratik Jain in Bengaluru; Editing by Tasim Zahid)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.03 USD | +5.77% | +3.87% | -14.26% |
06-28 | Savara Prices $100 Million Common Shares Offering | MT |
06-27 | JMP Securities Adjusts Price Target on Savara to $10 From $8, Maintains Market Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.26% | 663M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- SVRA Stock
- News Savara Inc.
- Savara's rare lung disease drug meets main goal in late-stage study